CD274 and hepatocellular carcinoma: The IMbrave150 clinical trial showed that PD-L1 inhibitor (atezolizumab) in combination with VEGF inhibitor (bevacizumab) presented the superior progression-free survival (PFS) and overall survival (OS) in comparison to sorafenib among unresectable HCC patients [5].